<?xml version="1.0" encoding="UTF-8"?>
<p>Today, there is no longer any technical limitation to making human mAbs in the broadest sense. Biological problems involving the determination of the type and nature of any synthetic or natural antibody, the advantages of different immunological compartments of B cells, and various assays for the qualification and quantification of mAbs have been extensively solved (Huang et al. 2020).</p>
